South Korea
· Delayed Price · Currency is KRW L&C BIO Co.,LTD Statistics
Total Valuation
L&C BIO Co.,LTD has a market cap or net worth of KRW 748.41 billion. The enterprise value is 863.91 billion.
| Market Cap | 748.41B |
| Enterprise Value | 863.91B |
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
L&C BIO Co.,LTD has 24.62 million shares outstanding. The number of shares has increased by 1.90% in one year.
| Current Share Class | 24.62M |
| Shares Outstanding | 24.62M |
| Shares Change (YoY) | +1.90% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.34% |
| Owned by Institutions (%) | 13.92% |
| Float | 16.76M |
Valuation Ratios
The trailing PE ratio is 5.40.
| PE Ratio | 5.40 |
| Forward PE | n/a |
| PS Ratio | 10.21 |
| PB Ratio | 2.55 |
| P/TBV Ratio | 8.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 118.63, with an EV/FCF ratio of -62.99.
| EV / Earnings | 6.21 |
| EV / Sales | 11.78 |
| EV / EBITDA | 118.63 |
| EV / EBIT | n/a |
| EV / FCF | -62.99 |
Financial Position
The company has a current ratio of 0.80, with a Debt / Equity ratio of 0.41.
| Current Ratio | 0.80 |
| Quick Ratio | 0.32 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 16.42 |
| Debt / FCF | -8.72 |
| Interest Coverage | 0.03 |
Financial Efficiency
Return on equity (ROE) is 62.27% and return on invested capital (ROIC) is 0.02%.
| Return on Equity (ROE) | 62.27% |
| Return on Assets (ROA) | 0.02% |
| Return on Invested Capital (ROIC) | 0.02% |
| Return on Capital Employed (ROCE) | 0.03% |
| Revenue Per Employee | 555.44M |
| Profits Per Employee | 1.05B |
| Employee Count | 132 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 0.77 |
Taxes
| Income Tax | -5.81B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.42% in the last 52 weeks. The beta is 0.71, so L&C BIO Co.,LTD's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | +40.42% |
| 50-Day Moving Average | 23,679.60 |
| 200-Day Moving Average | 21,181.20 |
| Relative Strength Index (RSI) | 63.98 |
| Average Volume (20 Days) | 490,759 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, L&C BIO Co.,LTD had revenue of KRW 73.32 billion and earned 139.08 billion in profits. Earnings per share was 5,558.47.
| Revenue | 73.32B |
| Gross Profit | 37.28B |
| Operating Income | 88.21M |
| Pretax Income | 134.56B |
| Net Income | 139.08B |
| EBITDA | 7.28B |
| EBIT | 88.21M |
| Earnings Per Share (EPS) | 5,558.47 |
Balance Sheet
The company has 14.10 billion in cash and 119.56 billion in debt, giving a net cash position of -105.46 billion or -4,283.85 per share.
| Cash & Cash Equivalents | 14.10B |
| Total Debt | 119.56B |
| Net Cash | -105.46B |
| Net Cash Per Share | -4,283.85 |
| Equity (Book Value) | 293.34B |
| Book Value Per Share | 12,488.61 |
| Working Capital | -22.72B |
Cash Flow
In the last 12 months, operating cash flow was -8.57 billion and capital expenditures -5.15 billion, giving a free cash flow of -13.72 billion.
| Operating Cash Flow | -8.57B |
| Capital Expenditures | -5.15B |
| Free Cash Flow | -13.72B |
| FCF Per Share | -557.10 |
Margins
Gross margin is 50.84%, with operating and profit margins of 0.12% and 189.70%.
| Gross Margin | 50.84% |
| Operating Margin | 0.12% |
| Pretax Margin | 183.53% |
| Profit Margin | 189.70% |
| EBITDA Margin | 9.93% |
| EBIT Margin | 0.12% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.16%.
| Dividend Per Share | 50.00 |
| Dividend Yield | 0.16% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 1.63% |
| Buyback Yield | -1.90% |
| Shareholder Yield | -1.73% |
| Earnings Yield | 18.58% |
| FCF Yield | -1.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 12, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Oct 12, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
L&C BIO Co.,LTD has an Altman Z-Score of 2.91 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.91 |
| Piotroski F-Score | 2 |